Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Agilon Health (AGL) Shares Outstanding (Diluted Average) (2020 - 2025)

Agilon Health's Shares Outstanding (Diluted Average) history spans 6 years, with the latest figure at $414.0 million for Q4 2025.

  • For Q4 2025, Shares Outstanding (Diluted Average) rose 0.73% year-over-year to $414.0 million; the TTM value through Dec 2025 reached $414.0 million, up 0.73%, while the annual FY2025 figure was $414.0 million, 0.73% up from the prior year.
  • Shares Outstanding (Diluted Average) reached $414.0 million in Q4 2025 per AGL's latest filing, roughly flat from $413.8 million in the prior quarter.
  • In the past five years, Shares Outstanding (Diluted Average) ranged from a high of $426.6 million in Q1 2023 to a low of $325.7 million in Q1 2021.
  • Average Shares Outstanding (Diluted Average) over 5 years is $400.7 million, with a median of $410.5 million recorded in 2023.
  • Peak YoY movement for Shares Outstanding (Diluted Average): soared 30.22% in 2022, then decreased 4.14% in 2024.
  • A 5-year view of Shares Outstanding (Diluted Average) shows it stood at $372.9 million in 2021, then rose by 9.44% to $408.2 million in 2022, then rose by 0.19% to $408.9 million in 2023, then increased by 0.5% to $411.0 million in 2024, then grew by 0.73% to $414.0 million in 2025.
  • Per Business Quant, the three most recent readings for AGL's Shares Outstanding (Diluted Average) are $414.0 million (Q4 2025), $413.8 million (Q3 2025), and $413.8 million (Q2 2025).